Physiologic aspects of aging: impact on cancer management and decision making, part II
- PMID: 16393480
- DOI: 10.1097/00130404-200511000-00005
Physiologic aspects of aging: impact on cancer management and decision making, part II
Abstract
In this second article of our two-part review, we focus on age-associated physiologic changes involving the nervous, endocrine, hematologic, immune, and musculoskeletal systems, with close attention to the interconnected nature of these systems. There is a well-known connection between the neuroendocrine and immune systems via the hypothalamic-pituitary-adrenal axis and via interaction by means of cytokines, hormones, and neurotransmitters. These changes may lead to a loss of integration and resiliency with age, thus decreasing the ability of the elderly patient with cancer to adapt to stressful circumstances. Prominent changes include decline in memory and cognition, and increased susceptibility to peripheral neuropathy. Hematologic and immune changes like reduced bone marrow reserve and increased susceptibility to infections have far reaching implications for cancer care in the elderly. Gradual decline in hormone levels, and changes in muscle and body composition, can lead to functional decline and frailty. Use of the clinical interventions suggested in this article, along with an appreciation of the interplay of these age-related physiologic changes and their consequences, allows oncology professionals to customize therapy and minimize side effects in the geriatric oncology patient.
Similar articles
-
Physiologic aspects of aging: impact on cancer management and decision making, part I.Cancer J. 2005 Nov-Dec;11(6):449-60. doi: 10.1097/00130404-200511000-00004. Cancer J. 2005. PMID: 16393479 Review.
-
The process of aging changes the interplay of the immune, endocrine and nervous systems.Mech Ageing Dev. 2001 Sep 30;122(14):1591-611. doi: 10.1016/s0047-6374(01)00289-5. Mech Ageing Dev. 2001. PMID: 11511399 Review.
-
Minireview: Neuro-immuno-endocrine modulation of the hypothalamic-pituitary-adrenal (HPA) axis by gp130 signaling molecules.Endocrinology. 2002 May;143(5):1571-4. doi: 10.1210/endo.143.5.8861. Endocrinology. 2002. PMID: 11956136 Review.
-
Age-related changes of neuro-endocrine-immune interactions in healthy humans.J Biol Regul Homeost Agents. 1997 Oct-Dec;11(4):143-7. J Biol Regul Homeost Agents. 1997. PMID: 9582614
-
Physiological aging in older adults with cancer: implications for treatment decision making and toxicity management.J Gerontol Nurs. 2010 Feb;36(2):26-37; quiz 38-9. doi: 10.3928/00989134-20091103-98. Epub 2010 Feb 5. J Gerontol Nurs. 2010. PMID: 19928710
Cited by
-
Adjuvant pharmacotherapy in the management of elderly patients with pancreatic cancer.Drugs Aging. 2013 Mar;30(3):155-65. doi: 10.1007/s40266-013-0049-0. Drugs Aging. 2013. PMID: 23338795 Review.
-
Metastatic neuroendocrine neoplasia treatments in patients over 70 years of age.Endocr Connect. 2018 Dec;7(12):1535-1541. doi: 10.1530/EC-18-0478. Endocr Connect. 2018. PMID: 30530877 Free PMC article.
-
Chemotherapy options in elderly and frail patients with metastatic colorectal cancer.Ann Gastroenterol. 2012;25(3):274-275. Ann Gastroenterol. 2012. PMID: 24713847 Free PMC article. No abstract available.
-
Capecitabine in combination with oxaliplatin and bevacizumab (AXELOX) as 1st line treatment for fit and vulnerable elderly patients (aged >70 years) with metastatic colorectal cancer (mCRC): a multicenter phase II study of the Hellenic Oncology Research Group (HORG).BMC Cancer. 2014 Apr 22;14:277. doi: 10.1186/1471-2407-14-277. BMC Cancer. 2014. PMID: 24755296 Free PMC article. Clinical Trial.
-
Real-world evidence on adjuvant chemotherapy in older adults with stage II/III colon cancer.World J Gastrointest Oncol. 2020 Jun 15;12(6):604-618. doi: 10.4251/wjgo.v12.i6.604. World J Gastrointest Oncol. 2020. PMID: 32699576 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources